For scientists seeking to create new medicines, the building blocks of their therapeutic ingenuity are often found in the existing substances that their colleagues and predecessors have created through decades of painstaking research. That’s one reason it’s awe-inspiring to behold the 4 million...
Sugar-coating can put a positive spin on things. But when it comes to some bacteria that cause diseases such as meningitis and pneumonia, their sugar coating is among the traits that make them so dangerous to humans
Derek Buhl, Principal Scientist and project leader developing Central Nervous System drugs, began his career working with autistic children, even learning sign language to communicate with an autistic boy who was also deaf.
Morris Birnbaum and his group are responsible for discovering the molecules and pathways that a new drug should target, as well as the clinical trials that give the first signs of evidence that a potential medicine works in the way it’s intended to.
Medical researchers turn to crowdsourcing in the coding community to crack DNA data challenges.
David Gray, a Senior Director in Pfizer’s Neuroscience Research Unit at Kendall Square, Cambridge, and expert in medicinal chemistry, is leading a team developing a potential first-in-class Parkinson’s disease treatment.
American scientist Florence Seibert developed a reliable test for TB, which has helped saved millions of lives.
Meet Mera Tilley, a geneticist and Director in Pfizer’s Early Clinical Development Group in Kendall Square in Cambridge, who’s an expert in genetic biomarkers, studying the link between people’s genes, inflammatory diseases and their response to medicines.